VivoSeq
Psychiatry

Opioid Dependence

55

Pipeline Programs↗

0

Active Trials↗

29

Companies Involved↗

Opioid Dependence is a moderately active landscape with 55 programs across 29 companies. The most active players are Eisai, Viatris Specialty LLC, Glaxo Dba Glaxosmithkline. 21 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

62/100

Attrition Rate

36/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

1 program

Phase 1V

Viatris Specialty LLC

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2M

Map77

1 program

Phase 2K

Kenvue Brands

1 program

Phase 2Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

98%

Small molecule

59 of 60 classified programs — the dominant modality here.

2%ALL OTHERSPeptide12%

Small molecule leads; the ring shows all 60 classified programs, each share of the total. Modality classified for 100% of 60 pipeline programs.

Analysis

Trial Status

44

clinical trials

Completed26 · 59%
Withdrawn11 · 25%
Terminated5 · 11%
Unknown status2 · 5%

Clinical Trials

Trial Activity

44 trials

Smoking Cessation & Opioid Dependence Treatment Integration
Completed·WWest Virginia University·Phase 2/3·NCT02854800·74 enrolled
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
Completed·National Institute on Drug Abuse (NIDA)·N/A·NCT00134914·10 enrolled
Buprenorphine Treatment for Opioid Dependence
Completed·YYale University·Phase 3·NCT02187198·9 enrolled
Opioid Dependence Treatment Therapies in Pregnancy
Completed·UUniversity of Pittsburgh·N/A·NCT03098407·55 enrolled
Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia
Completed·YYale University·Phase 2·NCT01863251·90 enrolled
Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Completed·TTitan Pharmaceuticals·Phase 3·NCT00630201·62 enrolled
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
Completed·OOrexo AB·Phase 3·NCT01848054·313 enrolled
Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary Care
Completed·NNew York State Psychiatric Institute·N/A·NCT00471042·30 enrolled
Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway
Completed·UUniversity of Oslo·Phase 3·NCT01717963·166 enrolled
Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Completed·TTitan Pharmaceuticals·Phase 3·NCT00447564·163 enrolled
Memantine and Naltrexone Treatment for Opioid Dependence
Completed·NNew York State Psychiatric Institute·Phase 2·NCT00125515·81 enrolled
Acute Effects of Cortisol on Heroin Craving in Opioid Dependence (Ghost-Basel)
Completed·PProf. Dominique de Quervain, MD·Phase 2·NCT01718964·30 enrolled
A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants
Completed·TTitan Pharmaceuticals·Phase 3·NCT02180659·177 enrolled
Pilot Study of Varenicline to Treat Opioid Dependence
Completed·MMayo Clinic·Phase 1·NCT01436474·21 enrolled
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
Completed·BBraeburn Pharmaceuticals·Phase 3·NCT02651584·428 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)